MYOS (NASDAQ:MYOS) Shares Up 9%
MYOS Co. (NASDAQ:MYOS) shot up 9% on Friday . The company traded as high as $1.44 and last traded at $1.33. 157,410 shares were traded during trading, an increase of 260% from the average session volume of 43,676 shares. The stock had previously closed at $1.22.
The company has a current ratio of 3.53, a quick ratio of 2.06 and a debt-to-equity ratio of 0.04.
MYOS (NASDAQ:MYOS) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.01. The firm had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.10 million. MYOS had a negative return on equity of 86.64% and a negative net margin of 660.40%. Analysts predict that MYOS Co. will post -0.5 EPS for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in MYOS. Pinnacle Associates Ltd. acquired a new position in MYOS during the fourth quarter worth approximately $172,000. Community Capital Management Inc. acquired a new position in MYOS during the first quarter worth approximately $57,000. Finally, Murphy Capital Management Inc. acquired a new position in MYOS during the first quarter worth approximately $32,000. 5.03% of the stock is currently owned by hedge funds and other institutional investors.
MYOS Company Profile (NASDAQ:MYOS)
MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Recommended Story: Beige Book
Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with MarketBeat.com's FREE daily email newsletter.